Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of Zynex stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $8.92, for a total value of $17,840.00. Following the completion of the transaction, the chief executive officer now owns 14,625,350 shares of the company’s stock, valued at approximately $130,458,122. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Thomas Sandgaard also recently made the following trade(s):

• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total value of $17,260.00.

Zynex Price Performance

Shares of NASDAQ:ZYXI opened at $8.76 on Friday. Zynex, Inc. has a 12 month low of $7.15 and a 12 month high of $13.77. The stock has a market cap of $279.01 million, a price-to-earnings ratio of 58.40 and a beta of 0.53. The stock’s 50 day moving average price is $8.11 and its 200 day moving average price is $9.09. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15.

Zynex (NASDAQ:ZYXI) last announced its earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The firm had revenue of $49.97 million for the quarter, compared to analysts’ expectations of $50.83 million. During the same quarter in the previous year, the company earned $0.10 earnings per share. The firm’s quarterly revenue was up .1% compared to the same quarter last year. Equities research analysts anticipate that Zynex, Inc. will post 0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ZYXI has been the topic of a number of recent analyst reports. HC Wainwright lifted their price target on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada cut their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Institutional Investors Weigh In On Zynex

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its holdings in shares of Zynex by 68.7% in the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after buying an additional 77,300 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Zynex by 0.5% in the first quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company’s stock valued at $14,684,000 after buying an additional 6,097 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Zynex by 66.5% in the second quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after buying an additional 118,615 shares in the last quarter. Quest Partners LLC increased its holdings in shares of Zynex by 646.7% in the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock valued at $120,000 after buying an additional 11,195 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System bought a new position in shares of Zynex in the first quarter valued at $137,000. Institutional investors own 29.68% of the company’s stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.